Emerging evidence suggests that design flaws of randomized controlled trials can result in over-or underestimation of the treatment effect size (ES). The objective of this study was to examine associations between treatment ES estimates and adequacy of sequence generation, allocation concealment, and baseline comparability among a sample of oral health randomized controlled trials. For our analysis, we selected all meta-analyses that included a minimum of 5 oral health randomized controlled trials and used continuous outcomes. We extracted data, in duplicate, related to items of selection bias (sequence generation, allocation concealment, and baseline comparability) in the Cochrane Risk of Bias tool. Using a 2-level meta-meta-analytic approach with a random effects model to allow for intra-and inter-meta-analysis heterogeneity, we quantified the impact of selection bias on the magnitude of ES estimates. We identified 64 meta-analyses, including 540 randomized controlled trials analyzing 137,957 patients. Sequence generation was judged to be adequate (at low risk of bias) in 32% (n = 173) of trials, and baseline comparability was judged to be adequate in 77.8% of trials. Allocation concealment was unclear in the majority of trials (n = 458, 84.8%). We identified significantly larger treatment ES estimates in trials that had inadequate/unknown sequence generation (difference in ES = 0.13; 95% CI: 0.01 to 0.25) and inadequate/unknown allocation concealment (difference in ES = 0.15; 95% CI: 0.02 to 0.27). In contrast, baseline imbalance (difference in ES = 0.01, 95% CI: -0.09 to 0.12) was not associated with inflated or underestimated ES. In conclusion, treatment ES estimates were 0.13 and 0.15 larger in trials with inadequate/unknown sequence generation and inadequate/unknown allocation concealment, respectively. Therefore, authors of systematic reviews using oral health randomized controlled trials should perform sensitivity analyses based on the adequacy of sequence generation and allocation concealment.
Background
Randomized controlled trials (RCTs) are a key component in the knowledge base that clinicians consistently rely on for everyday treatment-based decisions (Moher et al. 1998 ). Due to shortcomings in their conduct, RCTs are potentially exposed to biases (Göstemeyer et al. 2016) . Selection bias takes place in RCTs when individuals responsible for recruiting participants discriminate in enrolling them into the trial, according to a likely forthcoming treatment assignment (Higgins and Green 2008) . This is a particular concern when participants are recruited consecutively, rather than being enrolled in the trial at the same time (Berger and Exner 1999; Knottnerus and Tugwell 2014) . For this reason, adequate allocation concealment and randomization have been recognized as being crucial for preventing selection bias in RCTs (Schulz 1998) . In the same way, baseline comparability is believed to guarantee that the method of randomization is effective in ensuring that differences in baseline characteristics are not confounding the real effect (Altman and Dore 1990) . In fact, there is a debate whether testing for baseline comparability in RCTs is needed, given that the randomization process should account for any baseline differences of a trial's groups (de Boer et al. 2015) .
Evidence of association of bias with treatment effect estimates comes from published meta-epidemiological studies, which are studies that quantify the extent of bias in treatment effect size (ES) estimates related to trial quality in a group of meta-analyses (Sterne et al. 2002; Pildal et al. 2007; Wood et al. 2008) . To quantify bias in RCTs, meta-epidemiological studies use the ES
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estimate, which translates different scales into the same metric; consequently, they can be linked and compared (van Tulder et al. 2009 ). These studies have found associations between inadequate randomization or allocation concealment and inflated treatment ES estimates (i.e., exaggerated effectiveness of a treatment). Nevertheless, it has to be mentioned that significant associations were not found in some other reports (Juni et al. 1999; Balk et al. 2002) . Similarly, associations between baseline comparability and treatment ES estimates were not confirmed in 2 reports (Balk et al. 2002; van Tulder et al. 2009 ).
To date, methodological factors, including randomization and allocation concealment used to assess risk of bias, are derived only from meta-epidemiological studies of RCTs in medicine. Notably, a core set of items geared to assess the risk of selection bias was identified by many meta-epidemiological studies in medical subspecialty fields, such as cardiovascular disease, pediatrics, and surgery (Moher et al. 1998; Sterne et al. 2002; Pildal et al. 2007; Wood et al. 2008) . However, these meta-epidemiological studies were based mostly on dichotomous outcomes; only 2 meta-epidemiological studies focused on continuous outcomes (Nuesch et al. 2009; van Tulder et al. 2009 ). In the area of oral health, we located only 1 pilot metaepidemiological study (Faggion et al. 2015) , conducted at the level of meta-analyses, that quantified bias associated with periodontal trials via only 3 meta-analyses. That study found no differences in the magnitude of ES estimates when analyzing sequence generation and allocation concealment.
Therefore, the objectives of this study were to 1) examine associations between treatment ES estimates and adequacy of sequence generation, adequacy of allocation concealment, and baseline comparability and 2) determine the impact of potential additional factors, such as dental specialty, type of treatment, type of outcome, and the heterogeneity of meta-analyses on treatment ES estimates.
Methods
Protocol and Registration
The protocol of this meta-epidemiological study was registered on PROSPERO (Prospective Register of Systematic Reviews; CRD42014014070). This protocol was also peer reviewed and published a priori (Saltaji et al. 2014 ).
Selection of Meta-analyses
Inclusion criteria for the available meta-analyses were as follows:
• • The meta-analysis was in the field of dental, oral, or craniofacial research, and it evaluated a therapeutic intervention related to dental specialties. • • The meta-analysis examined a minimum of 1 continuous outcome and included at least 5 RCTs with quantitative data of treatment ES estimates.
Selection of Trials
The RCTs selected were included in the eligible meta-analyses and met the following inclusion-exclusion criteria:
• • The study was reported as a randomized clinical trial (Higgins and Green 2008) , and findings were reported in a way that allowed the calculation of treatment ES. • • The effect of a placebo, no-treatment, or standard-care control was compared with the effect of the intervention under investigation; however, RCTs comparing 2 active interventions were excluded when the direction of the effectiveness was not clearly stated by the study authors. • • The studies examined therapeutic interventions included in at least 1 of the 9 dental specialties recognized by the American Dental Association.
Information Sources
Six electronic databases were used to perform the searches from database inception to May 2014. A health information specialist helped to refine the search strategy. More details on specific search terms and specific combinations used in each database are presented in Appendix Table 2 . The searches were not limited to the English language, nor were they restricted by other means. The titles and abstracts retrieved from implementing the search strategy were screened by 2 independent assessors. Citations of systematic reviews deemed potentially relevant were selected, and the full-text articles were retrieved for complete screening. The final eligibility of full texts was determined by the same 2 reviewers, with disagreements resolved through consensus.
Data Extraction
Five reviewers from diverse health research areas formed the review panel that performed data extraction. Two team members (H.S., S.A.O.) conducted reviewer training to ensure consistency during data extraction. Training consisted of the panel reviewing 10 RCTs not included in the final set of trials, followed by assessment and feedback.
Data were extracted in duplicate by 2 independent assessors, with disagreements resolved through a consensus meeting. The first assessor (H.S.), a clinician with an oral health research background, performed a complete data extraction (N = 540, 100%), while the second assessor had a health research background. In cases of disagreement, where consensus could not be reached, a third assessor (S.A.O.) was solicited to aid in achieving complete consensus. Only consensus data were used for data analyses. The following sections describe details of data extracted.
Nonmethodological Characteristics. At the meta-analysis level, the following data elements were extracted: publication year, dental specialty, primary outcome assessed, type of comparison (e.g., active intervention vs. placebo, standard-care, or notreatment intervention), and number of included trials. Additionally, at the RCT level, the following elements were extracted: publication year, study design (e.g., parallel, splitmouth, crossover, or factorial), type of outcome (e.g., subjective vs. objective; Wood et al. 2008) , and number of centers (e.g., multicenter vs. single center).
Risk of Selection Bias
To assess selection bias in the selected RCTs, 3 methodological domains of the Cochrane Collaboration's Risk of Bias tool relevant to selection bias (Higgins et al. 2011) were examined: random sequence generation, allocation concealment, and baseline comparability. We used the same criteria of the Cochrane tool to score the items (i.e., high, low, or unclear; Appendix Table 3 ). In addition, methods of random sequence generation and allocation concealment implemented in included RCTs were classified (Armijo-Olivo et al. 2015) .
Treatment ES Estimate.
To calculate ESs, data on means, measures of variability (SDs and 95% confidence intervals [CIs]), and sample sizes were extracted for 1 outcome per trial, which was the primary outcome specified by the review/meta-analysis authors). If the review/meta-analysis primary outcome was binary (not continuous), not specified by the review/meta-analysis authors, or its meta-analysis did not include at least 5 trials, data were extracted on the continuous outcome of the metaanalysis with the largest number of included trials.
Sample Size Calculation
Our study sample size was estimated according to recommendations from studies by Berkman et al. (2014) , Hempel et al. (2011), and Fenwick et al. (2008) . From previous meta-epidemiological investigations (Nuesch et al. 2009 ), we anticipated obtaining a difference in treatment ES estimate of at least 0.15 (SE = 0.087) between trials with and without methodological limitations (Nuesch et al. 2009; Armijo-Olivo et al. 2015) . This magnitude of difference in treatment ES estimate has been claimed to resemble nearly one-fourth to one-half of a typical treatment ES estimate for interventions in fields similar to the field of dentistry (Fenwick et al. 2008; Nuesch et al. 2009 ). Accordingly, we employed a sample size of >500 RCTs included in >60 metaanalyses to demonstrate a meaningful difference. This is 2 to 3 times the number of trials included in previously published meta-epidemiological investigations (Nuesch et al. 2009; van Tulder et al. 2009; Hartling et al. 2014) .
Data Analysis
To illustrate the methodological characteristics of the RCTs included in this study, descriptive analyses were conducted (e.g., proportions and percentages for categorical data, such as the proportion of trials).
To examine associations among adequacy of randomization, allocation concealment, baseline comparability, and treatment effect estimates, a 2-level analysis was conducted per a meta-meta-analytic approach with a random effects model, based on recommendations from Sterne et al. (2002) . This type of statistical analysis was appropriate because the methodology used for our meta-epidemiological analysis accounts for heterogeneity among RCTs, within meta-analyses in the first step and among meta-analyses in the second step (Sterne et al. 2002; DerSimonian and Kacker 2007) . For the first level of analysis (within meta-analyses), standard treatment ES estimates were extracted from the primary outcome of each randomized trial, as described by Cohen (1988) , where a negative treatment ES estimate implies a beneficial effect of the interventional group. The type of comparison (e.g., treatment, control) was classified per the authors' classification of the comparison implemented in the meta-analysis reported in the review, and our classification was cross-checked by the principal assessor. Data from the RCTs in each selected meta-analysis were used. If a trial was found in >1 meta-analysis, it was used once in the meta-analysis with the fewest number of studies evaluated. The raw data for each trial were obtained from each meta-analysis and crosschecked with data reported in the primary trial. During this analytic process, the RCTs were divided into 2 groups-those that adequately addressed the evaluated quality items (e.g., adequate allocation concealment) and those that did not (e.g., "no" or unclear/unknown allocation concealment).
Two treatment ES estimates were calculated for each metaanalysis: 1 for all the studies that reported the characteristic of interest (e.g., allocation concealment) and 1 for studies that did not report that characteristic. We then calculated the difference between these 2 treatment ES estimates. A negative difference in treatment ES implied that trials with the characteristic of interest (e.g., adequate allocation concealment) had a more favorable effect for the tested intervention group. Inverse-variance random effects meta-analysis was used to derive pooled treatment ES estimates for each meta-analysis. The DerSimonian and Laird estimate of variance was then calculated to determine heterogeneity among the RCTs (DerSimonian and Kacker 2007). A metaregression technique was used for each meta-analysis to derive the difference between pooled treatment ES estimates of the studies with and without the characteristic of research interest, as well as its standard error.
The second level of analysis (among the meta-analyses) entailed pooling the results of the previous analysis (combined differences from all meta-analyses) to describe the difference in treatment ES estimate among trial components across all metaanalyses. Treatment ES estimates were combined at this stage, via inverse-variance random effects meta-analysis (DerSimonian and Kacker 2007) , to account for between-meta-analysis heterogeneity. The DerSimonian and Laird estimate of variance was calculated to determine heterogeneity among meta-analyses (DerSimonian and Kacker 2007), while all P values were 2-sided.
To determine the impact of potential additional factors (dental specialty, type of outcome, magnitude of treatment effect estimate, effect of heterogeneity of meta-analysis on treatment ES estimates), the meta-epidemiological analysis was stratified. Interaction tests accompanying these stratified analyses were based on Z scores according to the following factors: magnitude of treatment effect estimate (large, if ≤-0.5, vs. small, if >-0.5), heterogeneity of meta-analysis (high, if π2 ≥ 0.06, vs. low, if π2 < 0.06; this cutoff roughly corresponds to a difference of 1 between the largest and smallest treatment ES estimates), type of outcome (objective vs. subjective), and dental speciality (periodontal/implantology interventions vs. other interventions or vs. dental public health interventions). All analyses were performed with STATA 14 (StataCorp LP).
Results
Characteristics of Selected Meta-analyses and Randomized Trials
From 1,408 reviews included in the Oral Health Database of Systematic Reviews (Saltaji et al. 2013; Saltaji et al. 2016 ; which included dental, oral, and craniofacial reviews published between 1955 and 2014), 1,256 records were excluded per the information provided in the title or abstract. The remaining 152 full-text reports were retrieved for a more detailed evaluation, of which 64 systematic reviews with meta-analyses fulfilled the eligibility criteria. The complete list of excluded records and reasons for exclusion are available upon request. Ultimately, 64 meta-analyses including 540 randomized clinical trials analyzing 137,957 patients contributed to this investigation.
The 64 chosen therapeutic systematic reviews with meta-analyses were published between 2002 and 2014 (median year of publication: 2010; interquartile range: 2006 to 2012), of which 34.4% were Cochrane reviews (n = 22). The chosen meta-analyses included a median of 6 trials (interquartile range: 6 to 10). Nearly onethird of the trials were placebo controlled (n = 204, 37.8%), and two-thirds of those examined involved nonsurgical (n = 370, 68.5%) or nondrug (n = 359, 66.5%) interventions. One-fifth of the trials were multicenter trials, where the majority used parallel design (n = 372, 68.9%) and almost one-quarter used split-mouth design (n = 126, 23.3%). Appendix Table 1 provides further details on characteristics of the chosen meta-analyses.
Impact of Inadequate/Unknown Sequence Generation on Treatment ES Estimate
Sequence generation was judged to be adequate (at low risk of bias) in 32% (n = 173) of the trials, while sequence generation in 67.6% (n = 365) of the trials was assessed as unclear. Fiftytwo meta-analyses, including 467 trials involving 133,055 patients, provided information for this meta-epidemiological analysis. Results of the analysis showed that trials with inadequate/ unknown sequence generation had significantly larger treatment ES estimates (difference in ES = 0.13, 95% CI: 0.01 to 0.25, P = 0.037; Fig. 1) .
The results of the stratified analyses showed that differences in treatment ES estimates between trials with adequate and inadequate/ unknown sequence generation were significant (P < 0.001) in meta-analyses with a large treatment benefit in overall meta-analysis but not in meta-analyses with a small treatment benefit. However, none of the other factors considered had a statistically significant interaction ( Fig. 2A) .
Impact of Inadequate/Unknown Allocation Concealment on Treatment ES Estimate
Allocation concealment was judged to be at low risk of bias in 14.1% of trials (n = 76), while it was assessed as unclear in the majority of trials (n = 458, 84.8%). Thirty-nine meta-analyses, including 345 trials involving 110,797 patients, provided information for this meta-epidemiological analysis. Our metaepidemiological results showed that treatment ES estimates were significantly larger in RCTs with inadequate/unknown allocation concealment than in RCTs with adequate allocation Figure 1 . Difference in treatment effect size (ES) estimate between trials with adequate and inadequate/unknown sequence generation. A positive value (more than zero) across meta-analyses indicates that trials with inadequate/unknown sequence generation exaggerate the treatment ESs when compared with trials with adequate sequence generation. Diamond, difference in treatment ES estimate between trial components across all meta-analyses; square, proportional to weight used in meta-meta-analysis; horizontal arrow/line, a 95% confidence interval; solid vertical line, line of no difference in treatment ES estimate. concealment (difference in treatment ES estimate = 0.15, 95% CI: 0.02 to 0.27, P = 0.022; Fig. 3) .
The results of the stratified analyses showed that differences in treatment ES estimates between trials with adequate and inadequate/ unknown allocation concealment were significant (P < 0.001) only in meta-analyses with a large treatment benefit in overall meta-analysis but not in meta-analyses with a small treatment benefit (Fig. 2B) . The Table provides details on methods of sequence generation and allocation concealment in the trials.
Impact of Baseline Comparability on Treatment ES Estimate
Thirty-two meta-analyses, including 310 trials involving 121,213 patients, provided information for this meta-epidemiological analysis. Results of the analysis showed no statistically significant difference in treatment ES estimates between RCTs with balanced and imbalanced baseline characteristics (difference in ES = 0.01, 95% CI: -0.09 to 0.12, P = 0.804; Fig. 4) . The results of the stratified analyses showed that none of the stratifying factors had a statistically significant interaction (Fig. 2C) .
Discussion
To our knowledge, this investigation is one of the very few meta-epidemiological studies conducted in any medical field that examines continuous outcomes and/or employs an adequate sample size to examine the impact of selection bias on treatment ES estimates in RCTs. A potential limitation of previous metaepidemiological studies is that many of these studies were "underpowered," potentially leading to nonsignificant findings that are not true reflections of potential associations between a trial's quality and its treatment ES estimate (Berkman et al. 2014) . We included a large number of meta-analyses, several trial designs, and all dental specialties; this should increase statistical power and precision of the analysis and ensure generalizability of results. The number of trials assessed in our study was 2 to 3 times larger than that used in preceding metaepidemiological studies conducted in other medical fields. Furthermore, the strict methodology applied to data collection and data analysis, based on previous meta-epidemiological work by our research group, addressed potentially limiting factors associated with this type of methodological research. Our study showed that more than two-thirds of the trials did not clearly report sequence generation and/or allocation concealment, with 67.6%, 84.8%, and 22.2% of trials judged as having "unclear" bias in sequence generation, allocation concealment, and baseline comparability, respectively. While findings in the sequence generation domain were in agreement with findings of recent methodology studies (Savovic et al. 2012; Armijo-Olivo et al. 2015) , the proportion of trials that did not clearly report allocation concealment (84%) was higher than that reported in 2 recent studies by Armijo-Olivo et al. (2015) , in the field of rehabilitation medicine (71.8%, n = 393), and Hartling et al. (2014) , in the field of pediatrics (78.8%, n = 287). In a recently reported study (Pildal et al. 2007 ), the majority of trial protocols with unclear allocation concealment also had unclear allocation concealment in published trials, and if only studies with appropriate allocation concealment were included in reviews, nearly two-thirds of conclusions would have lost beneficial effects of the intervention. This is concerning because of the increased potential for bias due to limitations in study protocols in oral health trials; therefore, potential clinical decision-making policy in dental practice may be compromised.
Our study determined that 1) treatment ES estimates were 0.13 larger in trials with inadequate/unknown sequence generation than in trials with adequate sequence generation and 2) treatment ES estimates were 0.15 larger in trials with inadequate/ unknown allocation concealment than in trials with adequate allocation concealment. Thus, inadequate sequence generation and inadequate/unknown allocation concealment inflated treatment ES estimates by about one-fifth to one-fourth of the common treatment ES estimate reported in oral health research (Pandis 2012) , such as clinical outcomes in periodontology (Fenwick et al. 2008 ). However, baseline comparability was not associated with inflated or underestimated treatment ES estimates in our study.
With respect to the direction and magnitude of the treatment ES estimate, our results align with studies reporting that inadequate sequence generation could exaggerate treatment ES estimates by 51% (Kjaergard et al. 2001 ), 36% (Linde et al. 1999) , and 11% (Moher et al. 1998; Moher et al. 1999) , depending on the medical field examined. Similarly, inadequate allocation concealment has been associated with increased treatment ES estimates of 52% (Kjaergard et al. 2001) , 34% (Sterne et al. 2002) , and 10% (Pildal et al. 2007 ) when compared with adequately concealed trials. However, this association was not confirmed in other studies (Juni et al. 1999; Balk et al. 2002) . Previous reports examining effects of inadequate sequence generation and/or inadequate/unknown allocation concealment were restricted to RCTs in specific medical areas, such as pediatrics (Hartling et al. 2014 ), low-back pain (van Tulder et al. 2009 ), osteoarthritis (Nuesch et al. 2009) , and physical therapy (Armijo-Olivo et al. 2015) . These reports defined allocation concealment according to the Schulz tool for allocation concealment (Schulz et al. 1995; Moher et al. 1998; Sterne et al. 2002) and sequence generation according to the Jadad scale (Jadad et al. 1996; Linde et al. 1999; Moher et al. 1999) , the Cochrane Handbook (Higgins and Green 2008; Mhaskar et al. 2012) , or the Cochrane Collaboration's Risk of Bias tool (Higgins et al. 2011; Hartling et al. 2014; Armijo-Olivo et al. 2015) . Similarly, a meta-epidemiological study conducted in preclinical research showed that low trial quality was associated with inflated ES estimates of neurobehavioral outcome (Watzlawick et al. 2014) . While the aforementioned studies (Moher et al. 1998; Juni et al. 1999; Linde et al. 1999; Moher et al. 1999; Kjaergard et al. 2001; Balk et al. 2002 ) assessed dichotomous outcomes, 2 recent studies (Hartling et al. 2014; Armijo-Olivo et al. 2015) examined the association between treatment ES estimate and inadequate sequence generation and inadequate allocation concealment using continuous outcomes. However, while a meta-epidemiological analysis requires a large number of meta-analyses and trials, this was not the case in the majority of these studies. These inconsistent findings might be attributed to use of different statistical approaches (e.g., logistic regression, weighted regression, or the Bayesian model; Balk et al. 2002; Siersma et al. 2007 ); assessment of different types of interventions, outcomes, and populations (Berkman et al. 2014) ; and improper inclusion of trials with comparable active interventions (where identification of the direction of treatment effect is difficult). Improper inclusion of trials with comparable active interventions leads to inaccuracy when analyzing differences in treatment ES estimates.
Our results showing an insignificant influence of imbalance in baseline characteristics on treatment ES estimates align with 2 studies (Balk et al. 2002; van Tulder et al. 2009 ) that examined associations between baseline comparability and treatment ES estimates. The insignificant association between imbalances in baseline characteristics and treatment ES estimates found in our study and the aforementioned reports could be due to inclusion of only randomized trials, where baseline imbalances arise accidentally or by chance, and thus should not conceptually affect treatment ES estimates (Berkman et al. 2014; de Boer et al. 2015) . Randomized trial authors should report baseline characteristics of patients allocated to each intervention and judge whether a specific characteristic that was imbalanced among interventions has affected the trial's findings (Elkins 2015) .
On the basis of this evidence, authors of systematic reviews may consider excluding trials (conducted in the domains of dental, oral, and craniofacial research) with inadequate sequence generation and/or inadequate/unknown allocation concealment from meta-analyses, or they should perform sensitivity analyses based on the adequacy of sequence generation and allocation concealment in trials to possible estimates in different scenarios. Because of the expected impact of bias on treatment ES estimates, dental journal editors and reviewers should insist on adequate sequence generation and adequate allocation concealment in the conduct and reporting of RCTs submitted for publication.
Strengths and Limitations of the Study
This meta-epidemiological study provides an empirical analysis of the association between treatment ES estimates and selection bias in the domain of oral health research. The study has several limitations.
First, we examined published studies only (bias was based on reported methodological characteristics) and did not evaluate actual conduct of the RCTs. Accordingly, data extraction and analyses were based on information given by authors in published reports. This approach, though widely used, limits the identification of actual bias if trial authors do not adequately report study elements. For example, evidence from a methodology study (Pildal et al. 2005) showed that adequate allocation concealment and adequate sequence generation were reported in 18% and 21% of trial publications and in 44% and 36% of trial protocols, respectively.
Second, certain levels of heterogeneity are expected in any meta-epidemiological examination of the impact of bias on treatment ES estimates. Such studies analyze numerous entities (meta-analysis, trials, and participants) that have a distinct potential for heterogeneity (Berkman et al. 2014) . Also, the stratified analyses conducted in our study are likely less powered than the main conducted analysis. By applying a cautious methodology to data collection and analysis in this study and by assembling a large number of meta-analyses and trials, study power was increased and heterogeneity reduced.
Finally, this study did not assess the likely effects of interactions with other design biases. Such an assessment would have to include a multivariate analysis with a larger number of meta-analyses and trials (Hempel et al. 2012) . Future metaepidemiological assembling of a greater number of meta-analyses and trials should take other design biases into account by synthesizing results from different disciplines and data sets. 
